This segment is dedicated to the discovery, development, and commercialization of therapies for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS). The cornerstone of this segment is RELYVRIO/ALBRIOZA, a dual UPR-Bax apoptosis inhibitor. Research and development efforts are geared towards understanding the underlying mechanisms of neurodegeneration and identifying novel therapeutic targets. Technologies employed include advanced cell-based assays, biomarker discovery, and clinical trial design optimized for patient outcomes. The segment aims to improve the quality of life and extend the survival of patients affected by ALS and other debilitating neurological conditions. Future opportunities include expanding the therapeutic pipeline with innovative approaches and securing regulatory approvals in additional global markets. Partnerships with research institutions and patient advocacy groups are integral to advancing the segment's mission.

This segment focuses on addressing the unmet medical need in post-bariatric hypoglycemia (PBH). The lead asset in this program is Avexitide, a GLP-1 receptor antagonist acquired by Amylyx. Research and development activities are centered on understanding the pathophysiology of PBH and developing targeted therapies to manage the condition. The segment leverages clinical trials to evaluate the safety and efficacy of Avexitide in PBH patients. The goal is to provide a novel therapeutic option that can improve glycemic control and reduce the incidence of hypoglycemic episodes in individuals who have undergone bariatric surgery. Future opportunities include expanding the clinical development program and seeking regulatory approval for Avexitide in the treatment of PBH. Strategic collaborations with healthcare providers and patient support organizations are essential to advancing this segment.